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Background: Carbon monoxide (CO), a byproduct of heme degradation, is attracting growing attention from the
scientific community. At physiological concentrations, CO plays a role as a signal messenger that regulates a number
of physiological processes. CO releasing molecules are under evaluation in preclinical models for the management of
inflammation, sepsis, ischemia/reperfusion injury, and organ transplantation. Because of our discovery that nitric oxide
signaling actively down-regulates integrin affinity and cell adhesion, and the similarity between nitric oxide and
CO-dependent signaling, we studied the effects of CO on integrin signaling and cell adhesion.
Results: We used a cell permeable CO releasing molecule (CORM-2) to elevate intracellular CO, and a fluorescent Very
Late Antigen-4 (VLA-4, α4β1-integrin)-specific ligand to evaluate the integrin state in real-time on live cells. We show
that the binding of the ligand can be rapidly down-modulated in resting cells and after inside-out activation through
several Gαi-coupled receptors. Moreover, cell treatment with hemin, a natural source of CO, resulted in comparable
VLA-4 ligand dissociation. Inhibition of VLA-4 ligand binding by CO had a dramatic effect on cell-cell interaction in a
VLA-4/VCAM-1-dependent cell adhesion system.
Conclusions: We conclude that the CO signaling pathway can rapidly down-modulate binding of the VLA-4 -specific
ligand. We propose that CO-regulated integrin deactivation provides a basis for modulation of immune cell adhesion
as well as rapid cell mobilization, for example as shown for splenic monocytes in response to surgically induced
ischemia of the myocardium.
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Since the discovery that endogenous CO can serve as a
neurotransmitter [1] and that it exhibits anti-inflammatory
properties [2] the number of papers devoted to CO signal-
ing and therapeutic applications has increased every year
[3-6]. Since the roles of the two major gaseous messengers,
CO and nitric oxide (NO) are somewhat similar [7], and
our recent discovery of rapid effects of NO on integrin
ligand binding affinity and cell adhesion [8], we studied
the effects of CO on integrin regulation.* Correspondence: achigaev@salud.unm.edu
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unless otherwise stated.Integrins are cell adhesion receptors that are capable
of modulating rapid adhesion and de-adhesion events,
without a change in the number of molecules expressed
[9]. Ligand interactions with integrins represent the
molecular basis of integrin-dependent cell adhesion.
Integrin-dependent cell adhesion is controlled by the
conformational state of the molecule through ligand
binding affinity and extension that are regulated by a
number of signaling pathways initiated by other cellular
receptors. This so-called inside-out signaling serves as
the basis for rapid leukocyte arrest on endothelium, cell
migration and chemotaxis, mobilization, trafficking, and
interaction of immune cells [10,11]. α4β1-integrin (CD49d/
CD29, Very Late Antigen-4, VLA-4) is expressed on leuko-
cytes, dendritic cells, hematopoietic progenitors, and stem
cells, as well as cancer cells of differing origin [12,13].
The goal of the current study was to examine the effectsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 CO signaling cascade and small molecules used to
modulate this pathway. Endogenous carbon monoxide is
generated by heme oxygenase (HO). In cells CO reacts with
hemeproteins. One of the CO receptors is the guanylyl cyclase (GC)
that produces the intracellular messenger cyclic GMP (cGMP). cGMP
interacts with the cGMP-dependent protein kinase (PKG), which
phosphorylates multiple substrates, and participates in signal
propagation. The carbon monoxide donor provides an exogenous
source of CO. The natural HO substrate hemin increases CO production
because conversion of heme into biliverdin represents the rate-limiting
step in heme degradation [5]. The activator of soluble guanylyl cyclase
binds to GC, and induces enzyme activation in the absence of CO. The
cell permeable analog of cGMP diffuses across the plasma membrane,
and thus, activates cGMP-dependent signaling.
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regulation.
To date, a limited number of studies have been dedicated
to the effects of CO on leukocyte integrin-dependent adhe-
sion. The down-regulation of leukocyte extravasation
and leukocyte endothelial cell interaction, as well as the
effects on integrin or integrin ligand expression have been
reported [14-19]. To the best of our knowledge, this
report represents the first time that the effects of CO and
a natural source of CO, hemin, on integrin ligand binding
have been studied on live cells in real-time under inside-
out signaling conditions. Our findings provide a molecular
mechanism for inhibition of integrin-dependent leukocyte
adhesion and the beneficial effects of CO-associated ther-
apies in a number of pathologies [4].
Results
Carbon monoxide signaling and pathway modulation
Endogenous CO is produced inside cells as a product of
enzymatic degradation of heme catalyzed by the enzyme
heme oxygenase (HO) that consists of two isoforms:
HO-1 is inducible, and HO-2 is a constitutive form [20].
HO is localized in the cytosol and mitochondria [21].
The major source of heme for CO production is hemo-
globin, and other hemeproteins (Figure 1). CO has been
shown to stimulate soluble guanylyl cyclase, stimulate
vasodilatation, block cell proliferation, participate in neural
transmission, and inhibit platelet aggregation (see [20] and
references therein). CO targets several heme-containing
proteins and soluble guanylyl cyclase (sGC) was recognized
as the first and the most studied “CO receptor”. Multiple
physiological effects including vasodilatation and platelet
aggregation are attributed to the cGMP/PKG-dependent
arm of the CO signaling pathway. Other signaling mole-
cules such as p38 MAPK, ERK1/2, and JNK can be regu-
lated through other “CO sensors” [20,22].
To study the effects of CO/cGMP signaling in leuko-
cytes, we selected several small molecules that specifically
target this pathway (Figure 1). Tricarbonyldichlororuthe-
nium (II) dimer, Carbon Monoxide-Releasing Molecule 2
(CORM-2), can be described as a complex of a transition
metal ruthenium with carbon monoxide [23]. It spontan-
eously releases CO and is used as a carbon monoxide
donor. It exerts a vasodilatory effect in isolated blood ves-
sels, [24]. CORM-2 in vivo is shown to diminish adhesion
and accumulation of PMNs in injured mice [25,26].
Hemin is a heme substrate analog and an inducer of
HO-1 expression [19]. The conversion of one molecule of
heme into biliverdin results in the release of one molecule
of CO. The HO enzyme that generates CO from hemin is
expressed in our model system, and hemin addition has
been shown to decrease pro-inflammatory cytokine levels
in U937 cells [27]. BAY 41–2272 is an activator of soluble
guanylyl cyclase, which was shown to stimulate cGMPproduction [28]. N2,2’-O-dibutyrylguanosine 3’,5’-cyclic
monophosphate is a cell permeable cGMP analog that
activates protein kinase G [29]. All these molecules are
shown to stimulate different steps of the signaling path-
way (Figure 1), and therefore, are used to mimic CO-
dependent signaling.
The CO donor induces a rapid decrease in the binding of
the VLA-4 specific ligand
The VLA-4-specific ligand (LDV-FITC) is a small fluores-
cent probe based on the published structure of BIO1211, a
CD49d/CD29 specific antagonist [30-32]. The molecule
contains the Leu-Asp-Val (LDV) ligand binding motif from
the alternatively spliced connecting segment-1 (CS-1) pep-
tide of fibronectin. The major advantage of this probe is
that it can be used to detect VLA-4 conformational changes
on live cells in real-time in response to cell signaling
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varies in parallel with VCAM-1, the major natural VLA-4
ligand [35]. VCAM-1 contains the Ile-Asp-Ser (IDS) motif
homologous to LDV, and VLA-4 interaction with VCAM-1
can be blocked by LDV-containing molecules [35-37].
To determine the effect of the CO donor on resting
cells, samples were first treated with 25 nM LDV-FITC
(Figure 2A). This concentration is about 2 fold higher
than the dissociation constant for LDV-FITC binding to
U937 cells without activation (Kd ~12 nM, [30]). There-
fore, 70–80% of low affinity sites are occupied. Next, the
addition of CORM-2 resulted in the dose-dependent
dissociation of LDV-FITC that reached a steady-state
5–6 min after addition. Finally, an excess of unlabeled
competitor (LDV) was added to determine the non-specific
binding of the probe (Figure 2A). This induced rapid
LDV-FITC dissociation with a rate (koff ) similar to the
rate reported for resting cells [35]. To determine the
EC50 for the effect of CORM-2 on LDV-FITC binding,
the span of the single exponential fits for the dissoci-
ation curves after LDV addition was plotted versus the
logarithm of CORM-2 concentration (Figure 2B).
Next, to study the effect of the CO donor on cells acti-
vated through the “inside-out” signaling pathway, we used
U937 cells stably transfected with the non-desensitizing
mutant of the formyl peptide receptor (FPR). Because
serine and threonine in the C-terminal tail of GPCRs
phosphorylated by G protein-coupled receptor kinases
upon ligation are critical for the binding of arrestin and
receptor desensitization [38,39], we used a mutant FPR
lacking all serines and threonines (FPR ΔST) [40]. After
ligation of this receptor with a high affinity ligand N-
formyl-Met-Leu-Phe-Phe FPR signaling persists and the
high affinity of the VLA-4 ligand binding pocket is
maintained for thousands of seconds [8,34].
To observe real-time inside-out VLA-4 activation, cells
were first treated with 4 nM LDV-FITC (Figure 2C).
This concentration is below the dissociation constant
(Kd) for its binding to resting VLA-4 (low affinity state,
Kd ~12 nM), and above the Kd for physiologically acti-
vated VLA-4 (high affinity state, Kd ~1-2 nM) [30].
Thus, the transition from the low affinity to the high
affinity receptor state led to increased binding of the
probe (from ~25% to ~70-80% of receptor occupancy)
[41]. Therefore, the binding of additional LDV-FITC
molecules is detected as a rapid increase in the cell
fluorescence. Because the laser of the flow cytometer
excites only a small volume of solution around the cell,
the detection of probe binding is possible in a homoge-
neous (no-wash) format [42,43]. Next, the addition of
CORM-2 resulted in the dose-dependent dissociation
of LDV-FITC. Excess unlabeled competitor (LDV) was
used to determine the non-specific binding of the probe
(Figure 2C). The LDV-FITC dissociation rate (koff ) wasslower but similar to the rate reported for cells activated
through inside-out GPCR signaling [30,35]. The EC50 for
the effect of CORM-2 on activated cells was somewhat
higher than for resting cells (Figure 2D).
To establish whether the effect of CORM-2 was medi-
ated by CO, we conducted two control experiments
(Figure 2E, F). First, cells were treated with RuCl3 at a
concentration equal to the highest concentration used
of CORM-2 (150 μM). RuCl3 is a product of CORM-2
degradation, and therefore, it was used as a negative
control in CORM-2 experiments [44-47]. No statistically
significant effects of RuCl3 on LDV-FITC binding or dis-
sociation were detected (Figure 2E).
As a second control we took advantage of the limited
stability of CORM molecules [48]. First, a stock solution
of CORM-2 was prepared and incubated at room
temperature for 48 hours. The effect of this old solution
was compared to a fresh equimolar CORM-2 solution
prepared prior to the experiment (Figure 2F). The freshly
prepared solution induced significantly higher dissociation.
Thus, because gaseous CO is released into the air over
time, the difference between fresh and old CORM-2
solution may be attributed to the lower concentration
of CO in the old solution. Based on the two controls
we concluded that the effect of CORM-2 is attributed
to CO released by the CO donor.
Effect of the CO donor on the binding of VLA-4 specific
ligand during inside-out activation through CXCR4
and CXCR2
Cell activation through wild type GPCRs induces a rapid
and reversible VLA-4 affinity change due to receptor
desensitization [30]. Therefore, in CXCR4 and CXCR2
experiments, the CO donor was added two minutes prior
to the addition of GPCR ligands (Figure 3). The treatment
of cells stably transfected with wild type CXCR4 or CXCR2
significantly decreased the amplitude of the ligand-induced
LDV-FITC response. Thus, similar to a non-desensitizing
mutant of FPR the effect of the CO donor can be observed
for signaling through other G-protein coupled receptors.
This result is similar to the previously reported effect of
NO on GPCR-induced VLA-4 activation [8].
Hemin, a natural substrate of HO and a natural source of
CO, rapidly decreases binding of the VLA-4 specific ligand
Heme oxygenase is expressed in U937 cells [49-51], and
exogenous hemin can be used to modulate cell signaling
in this cell line [27,52]. To study the effect of hemin on
LDV-FITC binding on resting and activated cells, experi-
ments were conducted in a manner similar to the CO
donor experiments (Figure 2). Resting U937 cells were
treated with 25 nM LDV-FITC (Figure 4A). Next, appro-
priate concentrations of hemin were added. We observed
a slow dose-dependent decrease in the LDV-FITC signal.
Figure 2 Effect of CO donor on binding and dissociation of the LDV-FITC probe on resting and activated cells. LDV-FITC binding and
dissociation on U937 cells stably transfected with the non-desensitizing mutant FPR ΔST plotted as LDV-FITC fluorescence versus time. The data were
normalized to the level of the non-specific signal determined by addition of excess unlabeled competitor (LDV), and therefore, no autofluorescence
can be seen. A. The experiment involved sequential additions of the LDV-FITC, and different concentrations of CORM-2 or vehicle. The non-specific
binding of the probe was determined using LDV. Ligand dissociation rates (koff) were determined by fitting the dissociation part of the curves to the
single exponential equation. B. The span of the single exponential fits for the dissociation curves (from A after LDV addition) plotted versus logarithm
of CORM-2 concentration. Means ± SEM of two independent determinations are shown. The sigmoidal dose–response (Hill slope = 1) was fit using
GraphPad Prism. C. The sequential addition of the LDV-FITC, the high affinity FPR ligand (fMLFF), CORM-2 or vehicle, and LDV. LDV-FITC koffs were
determined as described for A. The level of LDV-FITC binding corresponding to resting cells is indicated by the dashed line. D. The span of single
exponential fits for the curves (from panel C) plotted versus logarithm of CORM-2 concentration. Means ± SEM of two independent determinations are
shown. The dose–response was fit analogously to B. E. The experiment involved addition of the LDV-FITC, RuCl3 or vehicle. F. The sequential addition
of the LDV-FITC, and CORM-2. The “old” CORM-2 was prepared by incubating the solution for 48 hours at room temperature. The non-specific binding
of the LDV-FITC probe was determined using LDV. For panels A, C, E, and F, a representative experiment of two independent experiments is shown.
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Figure 3 Effect of CO donor pretreatment on binding and dissociation of the LDV-FITC probe in cells stably transfected with CXCR4
and CXCR2, then treated with different Gαi-coupled receptor ligands. A. The experiment involved sequential addition of CORM-2 (75–150 μM,
CO donor) or DMSO (control), the fluorescent LDV-FITC probe (4 nM), CXCL12/SDF-1 (12 nM), and excess unlabeled LDV competitor (1 μM). Rapid
and reversible binding of the probe reflects the VLA-4 affinity change. B. The experiment involved sequential addition of CORM-2 (75μM, CO donor) or
DMSO (control), the fluorescent LDV-FITC probe (4 nM), CXCL8/IL-8 (20 nM), and excess unlabeled LDV competitor (1 μM). A representative experiment
of two independent experiments is shown.
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LDV-FITC probe, excess unlabeled competitor was
added 10–12 min later. As in the case of the CO donor,
the ligand dissociation rate (koff ) was similar to the rate
reported for resting cells. To determine the EC50 for
the effect of hemin on LDV-FITC binding, the span of
single exponential fits for the dissociation curves after
LDV addition was plotted versus the logarithm of hemin
concentration (Figure 4B). The effect of hemin was similar
to the effect of the CO donor on resting cells.
The effect of hemin on “inside-out” activated cells
(Figure 4C) has been studied in a manner analogous to
the CO donor experiments (Figure 2C). Cells were
treated with LDV-FITC, FPR ligand for cell activation,
appropriate concentrations of hemin, and the unlabeled
LDV competitor (Figure 4C). Analogous to the CO donor
results, the ligand dissociation rate (koff ) was similar to
the rate reported for activated cells, and the EC50 for the
effect of hemin on activated cells was comparable to the
EC50 for resting cells (Figure 4D). Thus, the natural
source of CO, hemin, exhibited activity that was analogous
to that of the artificial CO donor. Both compounds
induced rapid dissociation of the VLA-4 specific ligand.
Carbon monoxide donor produces a small effect on
VLA-4 subunit surface expression
To study the effect of CO signaling on VLA-4 surface
expression, cells were treated with the CO donor or
vehicle for 30 min at 37°C. Next, cells were stained with
primary labeled antibody against α4- and β1-integrin
subunits (Figure 5). Analysis of antibody binding revealed
a decrease in the surface expression of both integrinsubunits that varied from 10% to 26% in multiple experi-
ments. Given the small sample to sample variation this
difference was statistically significant (Figure 5B). How-
ever, this difference in the expression of VLA-4 subunits
detected after 30 min of CO donor treatment cannot
account for rapid and dramatic decrease in the VLA-4-
specific ligand binding that has been detected after CO
donor addition (Figure 2B,C).
Carbon monoxide donor diminishes VLA-4 /VCAM-1-
dependent cell adhesion
Next, to study the implications of the CO signaling pathway
on integrin-dependent cell adhesion, we utilized a VLA-4/
VCAM-1-specific real-time cell aggregation assay [35]. The
specificity of cell aggregation in this model system was
tested using anti-α4-integrin blocking mAb as well as
unlabeled LDV that completely blocked cell aggregation
[35,53]. Prior to mixing, U937 cells constitutively express-
ing VLA-4 were labeled with green fluorescent dye, and
B78H1 cells stably transfected with human VCAM-1 were
stained with red fluorescent dye (Figure 6A). The cell
aggregates were detected as red and green co-fluorescent
events in real-time. Cells were mixed and the baseline
aggregation data were collected for the first three minutes.
Next, the tube was removed and an aliquot of stock
solution of carbon monoxide donor CORM-2 in DMSO or
equal volume of vehicle (DMSO) were added. The tube
was rapidly replaced and data acquisition was reestablished.
The data were collected for up to 30 min (Figure 6B).
The CO donor treatment was sufficient to fully reverse
cell aggregation (Figure 6B). During the first three minutes
of the experiment no significant difference between the
Figure 4 Effect of hemin on binding and dissociation of the LDV-FITC probe on resting and activated U937 cells. LDV-FITC probe binding and
dissociation on U937 cells plotted as LDV-FITC fluorescence versus time. The data were normalized to the level of the non-specific signal determined by
the addition of excess unlabeled competitor (LDV 2 μM), and therefore, no cell autofluorescence can be seen. A. The experiment involved sequential
addition of the fluorescent LDV-FITC probe (25 nM), and different concentrations of hemin (6–100 μM) or DMSO (vehicle). The non-specific binding of
the LDV-FITC probe was determined using excess unlabeled competitor (LDV). Ligand dissociation rates (koff) were determined by fitting the dissociation
part of the curves (after LDV addition) to the single exponential equation. The range of koff is shown. B. The span of the single exponential fits for the
dissociation curves (from panel A after LDV addition) plotted versus logarithm of hemin concentration. Means ± SEM of two independent determinations
are shown (n = 2). The sigmoidal dose–response fit (Hill slope = 1) was obtained using GraphPad Prism software. C. The experiment was conducted using
U937 cells stably transfected with the FPR ΔST receptor, and involved sequential addition of the fluorescent LDV-FITC probe (4 nM), the high affinity FPR
ligand N-formyl-Met-Leu-Phe-Phe (100 nM), hemin (1.5-100 μM) or DMSO (control), and LDV (2 μM). LDV-FITC dissociation rates (koff) were determined as
described for panel A. D. The span of the single exponential fits for the dissociation curves (from panel C, after LDV addition) plotted versus logarithm of
hemin concentration. Means ± SEM of two independent determinations are shown (n = 2). The sigmoidal dose–response fit was obtained analogously
to panel B.
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cells continued to aggregate for ~2 minutes, and then
aggregate accumulation stopped and disaggregation
occurred. The sample treated with vehicle exhibited a
long-term accumulation of cell aggregates that reached
30-40% by the end of the experiment (Figure 6B). The
difference between samples treated with the CO donor and
untreated samples was statistically significant (Figure 6C).Thus, the CO donor added to the cell suspension in real-
time prevented VLA-4/VCAM-1-dependent aggregation.
The carbon monoxide donor decreases the binding
affinity of the VLA-4 specific ligand
Next, to quantify the effect of CO on VLA-4 specific ligand
binding affinity, we evaluated the binding of unlabeled LDV
ligand using a Ligand Induced Binding Site (LIBS) antibody.
Figure 5 Effect of CO donor on surface expression of VLA-4 (CD49d/CD29 heterodimer). U937 cells were treated with vehicle (DMSO,
control), and CO donor (150 μM CORM-2) for 30 min at 37°C. Next, cells were placed on ice and stained with primary labeled anti-CD29 and
anti-CD49d antibodies, or the isotype control. A. Histograms of anti-CD29 and anti-CD49d antibodies are shown in black, and the isotype control
is grey. B. Bar graphs of mean channel fluorescence (MCF) ± SEM (n =5) for unstained cells (autofluorescence), nonspecific binding to cells (isotype
control), cells treated with vehicle (DMSO), and cells treated with CORM-2 are shown (10,000 gated events for each sample were collected). One
representative experiment of three experiments is shown. * indicates means are significantly different (P <0.05) as estimated by the unpaired
t test analysis using GraphPad Prism software.
Chigaev et al. BMC Immunology 2014, 15:52 Page 7 of 15
http://www.biomedcentral.com/1471-2172/15/52Binding of ligands to integrins induces a series of conform-
ational changes that result in the exposure of previously
hidden epitopes. A LIBS antibody can recognize theseepitopes. This mAb feature can be used to detect ligand
occupied integrin receptors. The parental ligand molecule
(BIO1211) [32], and the LDV ligand are known to induce
Figure 6 Effect of CO donor on cell adhesion between U937 cells and VCAM-1-transfected B78H1 cells. A. Dot plot of flow cytometric
analysis of cell aggregation. Cells were labeled with red and green fluorescent dyes. Next, cells were mixed at 0 time point. During data acquisition
samples were maintained at 37°C, and continuously stirred with a magnetic stir bar. An increase in the number of aggregates was detected as green
and red co-fluorescent particles indicated by the circular gate. B. Real-time cell aggregation plotted as % aggregates (Agg, %) versus time. The data
were normalized to the non-specific aggregation determined as cell aggregation in the presence of excess unlabeled competitor (1 μM LDV). A
representative experiment out of two experiments is shown. C. Statistical significance of the CO donor effect on cell aggregation. The aggregate
percentage data from the last 5 min of the experiments (B) are compared using the unpaired t test. Means are significantly different (P < 0.05).
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affinity (Kd) for the unlabeled molecule, cells are incubated
with increasing concentrations of the ligand in the presence
of a constant concentration of the primary labeled LIBS
mAb [33]. Because flow cytometers have the ability to
discriminate between free and bound fluorescent molecules
in a homogeneous assay [42], the concentration of the
unlabeled ligand-receptor complex is proportional to the
fluorescence of the fluorophores associated with the mAbs
[54]. The major advantage of this approach, compared with
direct binding of a fluorescent ligand, is that there is no
limit to the ligand concentration. Because the LDV ligand
is unlabeled, no non-specific fluorescence increase with
ligand concentration is observed, and virtually no non-
specific antibody binding is detected [33,41,54]. This
assay allows the detection of integrin affinity changes
that differ by several orders of magnitude [55].
Cells were incubated in the presence of increasing
concentrations of unlabeled LDV and phycoerythrin-
labeled anti-CD29 LIBS antibody (HUTS-21) in the
presence or absence of the CO donor. As shownpreviously, the EC50 for mAb binding is similar to the
ligand dissociation constant (Kd) determined using other
methods [54]. We observed that the EC50s for LIBS
antibody binding for CORM-2 treated samples were
larger than for the vehicle treated controls by ~2 fold for
resting cells, and ~3 fold for FPR activated cells (Figure 6).
This indicated a decrease in the ligand binding affinity.
Also, the fact that the maximal binding of LIBS antibody
for CORM-2 treated samples was ~5-10% lower was
suggested by the change in VLA-4 receptor surface
expression (CD49d/CD29 complex) as detected using
anti-CD49d and anti-CD29 antibodies (Figure 5).
To evaluate the effects of the CO donor on the affinity
of the VLA-4 specific ligand we compared data obtained
using fluorescent LDV-FITC (Figures 2A,C and 4A,C)
with LDV binding detected using LIBS (Figure 7). Notice
that the two highest concentrations of the CO donor or
hemin induced very similar effects (see Figures 2A and
4A). The decrease in LDV-FITC binding on resting cells
saturated at ~30% for both compounds. Quantitatively,
in order to observe a decrease from 68% occupancy for
Figure 7 Effect of CO donor on binding of primary labeled LIBS
(HUTS-21) to U937 cells in the presence of different concentrations
of LDV. Mean fluorescence intensity plotted versus concentration of
unlabeled LDV. A. U937 cells were treated with vehicle (DMSO, control),
and CO donor (150 μM CORM-2) for 30 min at 37°C. Next, cells were
incubated with the indicated concentration of LDV in the presence of
excess HUTS-21 mAbs, washed, and fluorescence was measured. B. U937
cells stably transfected with the non-desensitizing FPR mutant were
treated with vehicle (DMSO, control), and CO donor (150 μM CORM-2)
for 30 min at 37°C in the presence of 100 nM fMLFF for cell activation.
Next, mAb binding was performed in a manner analogous to A. The
non-specific binding of HUTS-21, detected in the absence of LDV ligand,
was subtracted from the data. Means ± SEM of three independent
determinations are shown. The data were fitted using the sigmoidal dose–
response equation with GraphPad Prism software. One representative
experiment out of three independent experiments is shown.
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initial binding occupancy as calculated based on resting
VLA-4 Kd ~12 nM [30], and LDV-FITC concentration
25 nM) to ~30%, a ~4.8 fold increase in the Kd would be
required (at Kd ~58 nM, ligand concentration 25 nM,
receptor occupancy ~30% as derived from the one-site
hyperbolic binding equation).
For FPR activated cells, a decrease from ~80% initial
occupancy (Kd ~1 nM, and LDV-FITC concentration
4 nM), down to ~25% occupancy, requires a ~12 fold
increase in the Kd (at Kd ~12 nM, ligand concentra-
tion 4 nM). This suggests that the effect of CO is moresignificant in the case of integrins activated through
inside-out signaling. It is worth noting that Kd ~12 nM
corresponds to the Kd detected on resting cells, and the
real-time decrease in LDV-FITC binding after CORM-2
addition reached a plateau at a level that was close to the
level corresponding to the resting cell (before FPR activa-
tion, Figure 2C). This observation additionally supports
our calculations.
The effect of the CO donor on the ligand affinity
change detected using the LIBS antibody was smaller.
We detected only two to three fold differences in the
EC50s (Figure 7). The EC50 for fMLFF activated cells
(Figure 7B) was higher than the Kd estimated using dis-
sociation rate analysis [30,35,56]. This discrepancy may
be attributed to desensitization of FPR signaling after
long-term incubation in the presence antibodies. This
data additionally emphasizes the importance of rapid
real-time approaches for studying cell signaling [33].
The activator of soluble guanylyl cyclase and the cell
permeable cGMP analog decrease the binding affinity of
the VLA-4 specific ligand
The effects of BAY 41–2272, an activator of soluble
guanylyl cyclase and dibutyrylguanosine 3’,5’-cyclic mono-
phosphate, a cell permeable cGMP analog, (Figure 1) were
studied previously as part of our study of nitric oxide
signaling and VLA-4 regulation [8]. We found that BAY
41–2272 induced a rapid dose-dependent down-regulation
of LDV-FITC binding after activation through CXCR4,
CXCR2, and the non-desensitizing mutant of FPR. Cell
treatment with BAY 41–2272 exhibited faster dissociation
rates (koff ) indicating a decrease of the affinity of the VLA-4
specific ligand. DbcGMP also induced rapid and dose
dependent down-regulation of LDV-FITC binding [8].
Given the similarity between NO and CO signaling
and their functional roles, both gases stimulate guanylyl
cyclase [7,57]. These data support the role of the CO
signaling pathway in regulating VLA-4 conformation
and cell adhesion.
Discussion
Do cyclic nucleotides act as universal anti-adhesive
integrin regulators?
During the last few years we have described two signaling
pathways that can rapidly down-regulate the binding of
the VLA-4 specific ligand and cell adhesion: the Gαs-
coupled receptor signaling pathway and the NO/cGMP
signaling pathway [8,34]. CO-mediated VLA-4 inactiva-
tion is described in this report. One common feature of
these pathways is the modulation of nucleotide cyclases
leading to up-regulation of cyclic nucleotide (cAMP and
cGMP) levels. Similar downstream signaling mechanisms,
related to nucleotide-dependent kinases [58] and other
effectors, suggest the need for further evaluation of the
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dependent cell de-adhesion. The literature reveals that
these pathways can participate in cell mobilization, demar-
gination, detachment, or deployment, all of which can
be linked to a decrease of α4-integrin-dependent cell
adhesion.
For Gαs-coupled GPCRs, such as the β2-adrenergic
receptor or the H2-histamine receptor, specific ligand
agonists and antagonists, as well as an adenylyl cyclase
activator and a cell permeable cAMP analog were able
to rapidly modulate the affinity of the integrin and cell
adhesion after SDF-1/CXCR4 or FPR meadiated activation
[34]. This signaling pathway may participate in demarginat-
ing nonclassical monocytes [59] and CD8+ effector T-cells
[60], triggering rapid detachment of PBMCs attached to the
endothelium [61], mobilizing natural killer cells [62-64],
and playing a role in β2-adrenergic receptor and cAMP-
induced leukocytosis [65-67]. However, further studies
are needed to dissect the interplay between cytokines
and this signaling pathway [68]. Rapid mobilization of
hematopoietic stem progenitor cells (HSPCs) mediated
specifically through VLA-4 adhesion and SDF-1/CXCR4-
dependent signaling [55,69-75] was induced by β2-
adrenergic receptor agonists, and can be blocked by
a specific antagonist in mice [76]. We envision that
β2-adrenergic receptor/cAMP-dependent VLA-4 deacti-
vation [34] provides one of the molecular mechanisms
for regulating stem progenitor cell egress from the bone
marrow [77,78]. Another mechanism can be related to
NO signaling.
Our discovery that the NO/cGMP signaling pathway
rapidly deactivates high affinity VLA-4 pre-activated by
SDF-1/CXCR4 signaling and other Gαi-coupled GPCRs
[8] provides a plausible explanation for the observation
that links NO-mediated signaling and nitric oxide synthase
with stem and progenitor cell trafficking and mobilization.
Mice deficient in endothelial nitric oxide synthase (NOS3
or eNOS) exhibited impaired mobilization of endothelial
progenitor cells (EPC) from the bone marrow. The expres-
sion of CD29 (VLA-4 β1-subunit) and CXCR4 remained
unaltered in NOS3−/− mice, but neither the conformation
nor affinity state of the integrin was tested [79]. Bone
marrow stromal and vascular cells express large quantities
of NOS. These cells are envisioned to be a major source
of NO. Both stromal and vascular cells express VEGF-
receptor-2 (Flk-I), and VEGF is one of the major factors
mobilizing endothelial progenitors from bone marrow
[80,81]. VEGF has been shown to activate NO release
through AKT-dependent phosphorylation of eNOS
[80,82-85]. Thus, NO-triggered deactivation of VLA-4
could complement VEGF-induced stem cell mobilization
(see Figure 3 in [82]). It is possible that the effect of
NO is specific to CD34+ Flk-I+ EPCs. Under NO-deficient
conditions EPCs failed to be mobilized into the peripheralblood. The c-kit+Lin− HSPCs were not affected by nitric
oxide [86]. Thus, existing data support specific role of
cyclic nucleotide-related signaling as a regulator of cell
mobilization, demargination, or detachment under Gαs-
coupled GPCRs or NO signalling.
CO in macrophages
The effect of CO is typically attributed to the enzymatic
catabolism of heme, and the majority of CO (up to ~70%)
is produced from hemoglobin originating from the
breakdown of erythrocytes [20]. Splenic red-pulp mac-
rophages are responsible for the removal of senescent
red blood cells from the circulation, during filtration of
blood though the spleen [87]. These macrophages express
heme oxygenase-1 (HO-1) that metabolizes heme and
produces iron, biliverdin, and carbon monoxide [4]. HO-1
is essential for splenic macrophage function, since in
HO-1−/− mice macrophages are destroyed through expos-
ure to unmetabolized heme [88]. At the same time, the
spleen is reported to serve as a reservoir for resident mac-
rophages that can be rapidly deployed in the peripheral
blood in response to surgically induced ischemia of the
myocardium [89]. The data presented in this report suggest
a possible mechanism for the deployment phenomenon.
Erythrocyte damage can be induced by a number of
factors that include ischemia and inflammation. This may
lead to the increased clearance of red blood cells [90]. As
a result, increased phagocytosis by splenic macrophages
can lead to rapid up-regulation of heme catabolism and
intra-macrophage CO production. This is expected to
down-modulate integrin affinity and cell adhesion within
the phagocyte. It is also possible that CO can diffuse from
the phagocyte and act in a paracrine manner on macro-
phages residing in close proximity. The loss of cell adhe-
sion could result in macrophages entering the circulation
through the efferent splenic vein. This scenario seems
plausible specifically because of the role of α4-integrins in
splenic homing [87,91].
Another possible implication of the anti-adhesive impact
of CO signaling is in ischemia-reperfusion injury and
transplantation [4]. Adhesion molecules and specifically
β1- and β2- integrins are envisioned as feasible targets
for preventing reperfusion injury through blocking
leukocyte extravasation and recruitment [92-94]. The
successful application of CO for organ transplant could
be accompanied by reduced recruitment of leukocytes,
macrophages, and T-cells to the graft [95], and the overall
anti-inflammatory effect of CO could also be related to
blocking integrin-dependent immune cell adhesion [4].
Thus, it seems that the enzymatic catabolism of heme
in marcrophages and resulting intra-macrophage CO
production are critical for rapid down-regulation of
integrin-mediated cell adhesion, rapid re-entry of adherent
cells into circulation, or blocking of leukocyte extravasation
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that therapeutic modulation of this pathway can serve as a
viable alternative to a direct modulation of cell adhesion
using integrin antagonists for example.
CO, integrins, and immune response
The release and accumulation of hemin in peripheral blood
can result from hemolysis that occurs as a consequence
of bacterial infection [96]. Free heme plays a crucial role
in the pathogenesis of sepsis [97]. Since VLA-4 and
VLA-5 are known to regulate phagosome maturation
and microorganism clearance in macrophages [98], the
pathogen-induced damage of erythrocytes, which decreases
integrin binding through activation of the CO/cGMP path-
way, should promote pathogen survival. In particular, the
lipopolysaccharide-binding pattern recognition molecule
mindin (spondin-2) specifically interacts with CD49d/CD29
[99] though the LEV (Leu-Glu-Val) integrin-binding motif
[100] homologous to the LDV (Leu-Asp-Val) binding motif
in fibronectin [101]. Mindin is essential for microorganism
clearance because mindin-deficient macrophages show
defective phagocytosis [102]. Therefore, one would expect
that the binding of mindin to VLA-4 will be regulated
by CO in a manner similar to that of the LDV probe,
described in the current report. Thus, a release of large
amount of free heme and a subsequent CO production
in macrophages will provide a protection of pathogens
against microorganism clearance. However, no significant
effect of exogenous heme administration on the number
of bacterial colony-forming units in the blood and peri-
toneum of mice subjected to a nonlethal polymicrobial
infection were found, and the ability of heme to precipi-
tate sepsis was not directly related to the pathogen load
[97]. Nevertheless, because hemolysis can be caused by
pore-forming toxins produced by many blood-borne
pathogens [103], the amount of free heme should be
directly related to the bacterial load. The pore forming
toxins are known to contribute to the evasion of host
defence by the inhibition of innate immune responses
in macrophages [104]. Thus, a number of immuno-
logical phenomena related to pathogen-induced hemolysis
can be related to the regulation of VLA-4 integrin-
mediated binding of pattern recognition molecules,
phagosome maturation and microorganism clearance in
macrophages. The ability to release free heme, induce
production of large amount of CO, and thus block
integrin-dependent cell adhesion could be one of the
previously unrecognised immune evasion mechanisms
employed by haemolytic pathogens.
Conclusions
We conclude that CO from an artificial donor or a natural
CO source (hemin) down-modulated binding of the
VLA-4 integrin-specific ligand at rest and after inside-out activation through several Gαi-coupled receptors
activation. This results in a rapid down-modulation
of integrin-dependent cell adhesion. We propose that
CO-triggered integrin deactivation represents a novel
mechanism that provides a molecular basis for several
phenomena related to the mobilization of different cell
subsets, and the evasion of the immune response.Methods
Materials
The VLA-4-specific ligand 4-((N’-2-methylphenyl)ureido)-
phenylacetyl-L-leucyl-L-aspartyl-L-valyl-L-prolyl-L-alanyl-
L-alanyl-L-lysine (LDV) and its FITC-conjugated analog
(LDV-FITC probe) [30,33] were synthesized at Common-
wealth Biotechnologies. Mouse anti-human CD29/integrin
β1 chain, clone MAR4 (PE), mouse anti-human CD49d/
integrin α4 chain, clone 9F10 (PE), and isotype control
(mouse IgG1 κ, PE) clone MOPC-21 were purchased from
BD Biosciences and used according to the instructions of
the manufacturer. Human recombinant CXCL12/SDF-1α
and recombinant human CXCL8/IL-8 were obtained
from R&D Systems, Inc. All other reagents were from
Sigma-Aldrich. Stock solutions were prepared in DMSO,
at concentrations ~1000-fold higher than the final
concentration. Usually, 1 μl of stock solution was added
to 1 ml of cell suspension, yielding a final 0.1% DMSO
concentration. Control samples were treated with an
equal amount of pure DMSO (vehicle).Cell lines and transfectant construct
The human histiocytic lymphoma cell line U937 and mouse
melanoma cell line B78H1 were purchased from ATCC.
Wild type CXCR4 (CD184) receptor-stably transfected
U937 cells, wild type CXCR2 (IL8RB)-stably transfected
U937 cells, and the non-desensitizing FPR ΔST mutant
in U937 cells were prepared as described [105], and
were a gift of Dr. Eric Prossnitz (University of New
Mexico). For transfection of B78H1 cells, full-length
human VCAM-1 cDNA was a kind gift from Dr. Roy
Lobb of Biogen. The original construct [106] was sub-
cloned into the pTRACER vector (Life Technologies
Corp.). Transfection into B78H1 was done using the
Lipofectamine transfection reagent (Life Technologies
Corp). High receptor-expressing cells were sorted using
a MoFlo flow cytometer (Beckman Coulter Inc.). Cells
were grown at 37°C in a humidified atmosphere with
5% CO2 and 95% air in RPMI 1640 (supplemented with
2 mM L-glutamine, 100 units/ml penicillin, 100 μg/ml
streptomycin, 10 mM HEPES, pH 7.4, and 10% heat-
inactivated fetal bovine serum). Cells were counted
using the Coulter Multisizer/Z2 analyzer (Beckman Coulter
Inc.). For experiments, cells were suspended in warm
RPMI (37°C) at 1 × 106 cells/ml and used immediately.
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specific ligand
Kinetic analysis of the binding and dissociation of the
LDV-FITC probe was described previously [30,33]. Briefly,
cells (1 × 106 cells/ml) were preincubated in warm RPMI
under the appropriate conditions for 10–20 min at 37°C.
Flow cytometric data were acquired for up to 1024 s at
37°C while the samples were stirred continuously at
300 rpm with a 5 × 2 mm magnetic stir bar (Bel-Art
Products). Samples were analyzed for 30–120 s to
establish a baseline. The fluorescent ligand was added
and acquisition was re-established, creating a 5–10 s
gap in the time course. For real-time affinity activation
experiments, 4 nM LDV-FITC was added after establish-
ing a baseline. Then, data were acquired for 2–3 minutes,
and cells were treated with different GPCR ligands at
saturating concentration (10 times or higher than Kd).
In several experiments, cells were treated sequentially
with two or more different compounds. Acquisition was
re-established, and data were acquired continuously for
up to 1024 s.
The concentration of the LDV-FITC probe used in
activation experiments (4 nM) was below the dissociation
constant (Kd) for its binding to resting VLA-4 (low affinity
state, Kd ~ 12 nM), and above the Kd for physiologically
activated VLA-4 (high affinity state, Kd ~ 1–2 nM) [30].
Therefore, the transition from the low affinity to the high
affinity receptor state led to increased binding of the probe
(from ~25% to ~70 – 80% of receptor occupancy, as
calculated based on the one site binding equation),
which was detected as an increase in the mean fluores-
cence intensity. For kinetic dissociation measurements,
cell samples were preincubated with the fluorescent probe
(25 nM), treated with excess unlabeled LDV (2 μM), and
the dissociation of the fluorescent molecule was followed.
The resulting data were converted to mean fluorescence
intensity versus time using FCSQuery software developed
by Dr. Bruce Edwards (University of New Mexico).
Cell aggregation assay
The cell suspension aggregation assay has been described
previously [35,37]. Briefly, U937 cells were labeled with
the green fluorescence PKH67GL dye, and B78H1/
VCAM-1 transfectants were stained with the red fluores-
cence PKH26GL dye (Sigma-Aldrich). Labeled cells were
washed, resuspended in RPMI and stored on ice until used
in the assays. Control U937 cells were preincubated with
the LDV molecule for blocking. Prior to data acquisition,
cells were warmed to 37°C for 10 min separately and then
mixed. During data acquisition, the samples were stirred
with a 5 × 2-mm magnetic stir bar (Bel-Art Products,
Pequannock, NJ) at 300 rpm and kept at 37°C. The
number of cell aggregates containing red and green
co-fluorescent particles, and the number of singletswere followed in real-time. The percentage of aggregates
(Agg, %) was calculated as follows: Agg, % = (number of
aggregates/(number of aggregates + number of singlets)) ×
100. Experiments were performed using a FACScan flow
cytometer and Cell Quest software (Becton Dickinson,
San Jose, CA). The real-time aggregation kinetic data were
converted to Agg, % versus time using FCSQuery software
developed by Dr. Bruce Edwards (University of New
Mexico). Figures were prepared using Summit V4.3 soft-
ware (Beckman Coulter Inc.).
Statistical analysis
Curve fits and statistics were performed using GraphPad
Prism version 4.00 for Windows, GraphPad Software, San
Diego California USA, www.graphpad.com. Each experi-
ment was repeated two or three times. The experimental
curves represent the mean of two or more independent
runs. SEM was calculated using GraphPad Prism.
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